CAN1012 in Pre-Malignant DCIS and LCIS
CAN1012 in Pre-Malignant DCIS and LCIS
Recruiting · NCT07408856 · Registry updated 2026-09-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CAN1012 in Pre-Malignant DCIS and LCIS | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, lobular breast carcinoma in situ, neoplasm, skin disorder | Recruiting | Phase 1 | 2026-09-24 | NCT07408856 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CanWell Pharma Inc. | 2 |
| Providence Health & Services | 35 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Providence Portland Cancer Institute - Franz Clinic | Portland | United States | 4 |